Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Capital Expenditures (2016 - 2025)

Ultragenyx Pharmaceutical has reported Capital Expenditures over the past 10 years, most recently at -$62000.0 for Q4 2025.

  • Quarterly Capital Expenditures fell 100.76% to -$62000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.0 million through Dec 2025, down 66.67% year-over-year, with the annual reading at $5.0 million for FY2025, 66.67% down from the prior year.
  • Capital Expenditures was -$62000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $4.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $29.8 million in Q2 2023 and troughed at -$38.1 million in Q4 2021.
  • The 5-year median for Capital Expenditures is $3.5 million (2023), against an average of $5.0 million.
  • Year-over-year, Capital Expenditures plummeted 183.04% in 2021 and then skyrocketed 1792.29% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$38.1 million in 2021, then skyrocketed by 93.5% to -$2.5 million in 2022, then soared by 153.92% to $1.3 million in 2023, then soared by 512.38% to $8.2 million in 2024, then plummeted by 100.76% to -$62000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Capital Expenditures are -$62000.0 (Q4 2025), $4.0 million (Q3 2025), and -$302000.0 (Q2 2025).